Compare ADMA Biologics Inc (ADMA) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.82. The key difference: Roundhill Russell 2000 0DTE Covered Call Strat ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | RDTE | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $34.73 |
52-Week Low | $7.60 | $26.40 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
RDTE trades at $29.33 with a slight 0.55% daily gain. Technical indicators show mixed signals with a neutral overall rating, while moving averages suggest a bullish bias. The stock has demonstrated consistent dividend payments throughout 2026, though key valuation metrics remain unavailable. Recent news highlights concerns about the ETF's structural risks and capital erosion potential despite high yield characteristics.
The outlook remains cautious given structural concerns about the covered call strategy's limitations. While regular dividends provide income appeal, the strategy's capped upside and full downside exposure present significant risk factors that may outweigh yield benefits for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
